Department of Neurology, NYU Grossman School of Medicine, New York, New York, USA.
Department of Neurology and Neurological Rehabilitation, Shanghai Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), School of Medicine, Tongji University, Shanghai, China.
Mov Disord. 2023 Oct;38(10):1850-1860. doi: 10.1002/mds.29558. Epub 2023 Jul 17.
Long-term use of levodopa for Parkinson's disease (PD) treatment is often hindered by development of motor complications, including levodopa-induced dyskinesia (LID). The substantia nigra pars reticulata (SNr) and globus pallidus internal segment (GPi) are the output nuclei of the basal ganglia. Dysregulation of SNr and GPi activity contributes to PD pathophysiology and LID.
The objective of this study was to determine whether direct modulation of SNr GABAergic neurons and SNr projections to the pedunculopontine nucleus (PPN) regulates PD symptoms and LID in a mouse model.
We expressed Cre-recombinase activated channelrhodopsin-2 (ChR2) or halorhodopsin adeno-associated virus-2 (AAV2) vectors selectively in SNr GABAergic neurons of Vgat-IRES-Cre mice in a 6-hydroxydopamine model of PD to investigate whether direct optogenetic modulation of SNr neurons or their projections to the PPN regulates PD symptoms and LID expression. The forepaw stepping task, mouse LID rating scale, and open-field locomotion were used to assess akinesia and LID to test the effect of SNr modulation.
Akinesia was improved by suppressing SNr neuron activity with halorhodopsin. LID was significantly reduced by increasing SNr neuronal activity with ChR2, which did not interfere with the antiakinetic effect of levodopa. Optical stimulation of ChR2 in SNr projections to the PPN recapitulated direct SNr stimulation.
Modulation of SNr GABAergic neurons alters akinesia and LID expression in a manner consistent with the rate model of basal ganglia circuitry. Moreover, the projections from SNr to PPN likely mediate the antidyskinetic effect of increasing SNr neuronal activity, identifying a potential novel role for the PPN in LID. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
长期使用左旋多巴治疗帕金森病(PD)常因运动并发症的发展而受阻,包括左旋多巴诱导的运动障碍(LID)。黑质网状部(SNr)和苍白球内节(GPi)是基底神经节的输出核。SNr 和 GPi 活性的失调导致 PD 的病理生理学和 LID。
本研究旨在确定直接调节 SNr 抑制性神经元和 SNr 投射到脑桥被盖核(PPN)是否调节 PD 症状和 LID 在小鼠模型中。
我们在 6-羟多巴胺诱导的 PD 模型中,在 Vgat-IRES-Cre 小鼠的 SNr 抑制性神经元中表达 Cre 重组酶激活的通道视紫红质-2(ChR2)或卤化视紫红质腺相关病毒-2(AAV2)载体,以研究直接光遗传学调节 SNr 神经元或其投射到 PPN 是否调节 PD 症状和 LID 表达。采用前爪踏步行走任务、小鼠 LID 评分量表和旷场运动来评估运动不能和 LID,以测试 SNr 调节的效果。
抑制 SNr 神经元活性的卤化视紫红质可改善运动不能。ChR2 增加 SNr 神经元活性可显著减少 LID,而不干扰左旋多巴的抗运动不能作用。ChR2 在 SNr 投射到 PPN 的光刺激再现了直接 SNr 刺激。
SNr 抑制性神经元的调节以与基底神经节电路的速率模型一致的方式改变运动不能和 LID 表达。此外,来自 SNr 到 PPN 的投射可能介导增加 SNr 神经元活性的抗运动障碍作用,这表明 PPN 在 LID 中可能具有潜在的新作用。